Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment.

Spizzo G, Siebert U, Gastl G, Voss A, Schuster K, Leonard R, Seeber A.

Cost Eff Resour Alloc. 2019 Oct 21;17:23. doi: 10.1186/s12962-019-0191-6. eCollection 2019.

2.

Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies.

Zimmer K, Kocher F, Spizzo G, Salem M, Gastl G, Seeber A.

Comput Struct Biotechnol J. 2019 Mar 26;17:447-453. doi: 10.1016/j.csbj.2019.03.012. eCollection 2019. Review.

3.

Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer: Data of a Pooled Analysis.

Seeber A, Chahine G, Nasr F, Dean A, Miranova M, Jameson G, Robert N, Gastl G, Zwierzina H.

Cancer J. 2019 Mar/Apr;25(2):73-79. doi: 10.1097/PPO.0000000000000358.

PMID:
30896526
4.

Correction to: Ruxolitinib therapy formyelofibrosis in Austria : Consensus on therapy management.

Krauth MT, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Keil F, Krippl P, Melchardt T, Petzer A, Rumpold H, Sliwa T, Wöhrer S, Wölfler A, Gisslinger H.

Wien Klin Wochenschr. 2019 Jan;131(1-2):47. doi: 10.1007/s00508-018-1428-7.

5.

Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management.

Krauth MT, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Keil F, Krippl P, Melchardt T, Petzer A, Rumpold H, Sliwa T, Wöhrer S, Wölfler A, Gisslinger H.

Wien Klin Wochenschr. 2018 Sep;130(17-18):495-504. doi: 10.1007/s00508-018-1365-5. Epub 2018 Jul 24. Erratum in: Wien Klin Wochenschr. 2019 Jan;131(1-2):47.

6.

Austrian recommendations for the management of polycythemia vera.

Burgstaller S, Buxhofer-Ausch V, Sliwa T, Beham-Schmid C, Gastl G, Geissler K, Melchardt T, Krauth M, Krippl P, Petzer A, Rumpold H, Wölfler A, Gisslinger H.

Wien Klin Wochenschr. 2018 Sep;130(17-18):535-542. doi: 10.1007/s00508-018-1359-3. Epub 2018 Jul 19. Review.

PMID:
30027395
7.

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours.

Fiedler W, Stoeger H, Perotti A, Gastl G, Weidmann J, Dietrich B, Baumeister H, Danielczyk A, Goletz S, Salzberg M, De Dosso S.

ESMO Open. 2018 Jun 23;3(4):e000381. doi: 10.1136/esmoopen-2018-000381. eCollection 2018.

8.

Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness.

Boesch M, Onder L, Cheng HW, Novkovic M, Mörbe U, Sopper S, Gastl G, Jochum W, Ruhstaller T, Knauer M, Ludewig B.

Oncoimmunology. 2018 Jan 3;7(4):e1414129. doi: 10.1080/2162402X.2017.1414129. eCollection 2018.

9.

Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia.

Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, Schalling M, Krauth MT, Thiele J, Ruckser R, Gastl G, Gisslinger H.

Eur J Haematol. 2018 Mar 30. doi: 10.1111/ejh.13070. [Epub ahead of print]

PMID:
29603799
10.

Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.

Seeber A, Gunsilius E, Gastl G, Pircher A.

Oncol Res Treat. 2018;41(4):188-193. doi: 10.1159/000488301. Epub 2018 Mar 23.

11.

High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.

Seeber A, Klinglmair G, Fritz J, Steinkohl F, Zimmer KC, Aigner F, Horninger W, Gastl G, Zelger B, Brunner A, Pichler R.

Cancer Sci. 2018 May;109(5):1583-1591. doi: 10.1111/cas.13560. Epub 2018 Apr 16.

12.

New insights into sinusoidal obstruction syndrome.

Piccin A, Sartori MT, Bisogno G, Van Schilfgaarde M, Saggiorato G, Pierro AMD, Corvetta D, Marcheselli L, Andrea M, Gastl G, Cesaro S.

Intern Med J. 2017 Oct;47(10):1173-1183. doi: 10.1111/imj.13550.

PMID:
28707749
13.

Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples.

Boesch M, Hoflehner E, Wolf D, Gastl G, Sopper S.

J Vis Exp. 2017 May 10;(123). doi: 10.3791/55634.

14.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

15.

Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.

Piccin A, Steurer M, Feistritzer C, Murphy C, Eakins E, Van Schilfgaarde M, Corvetta D, Di Pierro AM, Pusceddu I, Marcheselli L, Gambato R, Langes M, Veneri D, Perbellini O, Pacquola E, Gottardi M, Gherlinzoni F, Mega A, Tauber M, Mazzoleni G, Piva E, Plebani M, Krampera M, Gastl G.

Transl Res. 2017 Jun;184:21-34. doi: 10.1016/j.trsl.2017.02.001. Epub 2017 Feb 14.

PMID:
28259616
16.

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.

Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D.

J Clin Oncol. 2017 Jan 10;35(2):175-184. Epub 2016 Nov 7.

PMID:
28056193
17.

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.

Seeber A, Gastl G, Ensinger C, Spizzo G, Willenbacher W, Kocher F, Leitner C, Willenbacher E, Amann A, Steiner N, Eisterer W, Voss A, Russell K, Zwierzina H.

Genes Cancer. 2016 Sep;7(9-10):301-308. doi: 10.18632/genesandcancer.121.

18.

Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.

Sliwa T, Beham-Schmid C, Burgstaller S, Buxhofer-Ausch V, Gastl G, Geissler K, Krauth M, Krippl P, Lang A, Petzer A, Wöhrer S, Wölfler A, Gisslinger H.

Wien Klin Wochenschr. 2017 May;129(9-10):293-302. doi: 10.1007/s00508-016-1120-8. Epub 2016 Dec 13.

PMID:
27966016
19.

Targeted Therapy of Colorectal Cancer.

Seeber A, Gastl G.

Oncol Res Treat. 2016;39(12):796-802. Epub 2016 Nov 22. Review.

PMID:
27889786
20.

Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.

Boesch M, Sopper S, Zeimet AG, Reimer D, Gastl G, Ludewig B, Wolf D.

Biochim Biophys Acta. 2016 Dec;1866(2):276-289. doi: 10.1016/j.bbcan.2016.10.003. Epub 2016 Oct 15. Review.

21.

Platelet gel: a new therapeutic tool with great potential.

Piccin A, Di Pierro AM, Canzian L, Primerano M, Corvetta D, Negri G, Mazzoleni G, Gastl G, Steurer M, Gentilini I, Eisendle K, Fontanella F.

Blood Transfus. 2017 Jul;15(4):333-340. doi: 10.2450/2016.0038-16. Epub 2016 Jul 25. Review.

22.
23.

Healing of a soft tissue wound of the neck and jaw osteoradionecrosis using platelet gel.

Piccin A, Di Pierro AM, Tagnin M, Russo C, Fustos R, Corvetta D, Primerano M, Magri E, Conci V, Gentilini I, Burkia Stocker E, Negri G, Mazzoleni G, Gastl G, Fontanella F.

Regen Med. 2016 Jul;11(5):459-63. doi: 10.2217/rme-2016-0031. Epub 2016 Jun 27.

PMID:
27346565
24.

High prevalence of side population in human cancer cell lines.

Boesch M, Zeimet AG, Fiegl H, Wolf B, Huber J, Klocker H, Gastl G, Sopper S, Wolf D.

Oncoscience. 2016 Apr 10;3(3-4):85-87. doi: 10.18632/oncoscience.300. eCollection 2016.

25.

Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.

Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, Ruckser R, Gastl G, Gisslinger H.

Eur J Haematol. 2016 Dec;97(6):511-516. doi: 10.1111/ejh.12759. Epub 2016 May 23.

PMID:
27037858
26.

Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer.

Seeber A, Untergasser G, Spizzo G, Terracciano L, Lugli A, Kasal A, Kocher F, Steiner N, Mazzoleni G, Gastl G, Fong D.

Int J Cancer. 2016 Aug 1;139(3):657-63. doi: 10.1002/ijc.30099. Epub 2016 Apr 15.

27.

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.

Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, Wiktor-Jedrzejczak W, Rea D, Coriu D, Brümmendorf TH, Porkka K, Saglio G, Gastl G, Müller MC, Schuld P, Di Matteo P, Pellegrino A, Dezzani L, Mahon FX, Baccarani M, Giles FJ.

Leukemia. 2016 Jan;30(1):57-64. doi: 10.1038/leu.2015.270. Epub 2015 Oct 6.

28.

Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.

Siebert U, Jahn B, Rochau U, Schnell-Inderst P, Kisser A, Hunger T, Sroczynski G, Mühlberger N, Willenbacher W, Schnaiter S, Endel G, Huber L, Gastl G; Oncotyrol HTA & Outcomes Research Working Group.

Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):330-40. doi: 10.1016/j.zefq.2015.06.012. Epub 2015 Jul 28.

PMID:
26354133
29.

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.

Seeber A, Braicu I, Untergasser G, Nassir M, Fong D, Botta L, Gastl G, Fiegl H, Zeimet A, Sehouli J, Spizzo G.

Oncotarget. 2015 Sep 22;6(28):25017-23. doi: 10.18632/oncotarget.4496.

30.

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R.

Blood. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10.

31.

Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.

Ninkovic M, Fiegl M, Mian M, Mondello P, Kocher F, Waldthaler C, Verdorfer I, Steurer M, Gastl G, Pircher A.

Anticancer Res. 2015 Sep;35(9):5129-39.

PMID:
26254418
32.

Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.

Boesch M, Zeimet AG, Rumpold H, Gastl G, Sopper S, Wolf D.

Stem Cells Transl Med. 2015 Sep;4(9):1028-32. doi: 10.5966/sctm.2015-0054. Epub 2015 Jul 1.

33.

Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.

Seeber A, Martowicz A, Spizzo G, Buratti T, Obrist P, Fong D, Gastl G, Untergasser G.

BMC Cancer. 2015 May 7;15:372. doi: 10.1186/s12885-015-1371-1.

34.

Treg(s) in Cancer: Friends or Foe?

Wolf D, Sopper S, Pircher A, Gastl G, Wolf AM.

J Cell Physiol. 2015 Nov;230(11):2598-605. doi: 10.1002/jcp.25016. Review.

PMID:
25913194
35.

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo.

Steiner N, Ribatti D, Willenbacher W, Jöhrer K, Kern J, Marinaccio C, Aracil M, García-Fernández LF, Gastl G, Untergasser G, Gunsilius E.

Oncotarget. 2015 Apr 10;6(10):8200-9.

36.

Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study.

Tortorella G, Piccin A, Tieghi A, Marcheselli L, Steurer M, Gastl G, Codeluppi K, Fama A, Santoro U, Birtolo C, Gugliotta G, Cortelazzo S, Gugliotta L; Gimema Foundation project “Registro Italiano Trombocitemie (RIT)”.

Leuk Res. 2015 Jun;39(6):592-8. doi: 10.1016/j.leukres.2015.03.014. Epub 2015 Mar 28.

PMID:
25850727
37.

The "Blood Apple Tree". A simple and straightforward metaphor for teaching blood and bone marrow physiology.

Piccin A, Gastl G.

Blood Transfus. 2015 Apr;13(2):318-9. doi: 10.2450/2015.0309-14. Epub 2015 Feb 26. No abstract available.

38.

Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example.

Rochau U, Jahn B, Qerimi V, Burger EA, Kurzthaler C, Kluibenschaedl M, Willenbacher E, Gastl G, Willenbacher W, Siebert U.

Crit Rev Oncol Hematol. 2015 May;94(2):164-78. doi: 10.1016/j.critrevonc.2014.12.017. Epub 2014 Dec 31. Review.

PMID:
25620327
39.

Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia.

Piccin A, Steurer M, Mitterer M, Blöchl EM, Marcheselli L, Pusceddu I, Marabese A, Bertozzi I, Corvetta D, Randi ML, Elli E, Pogliani EM, Veneri D, Perbellini O, Krampera M, Pacquola E, Gottardi M, Tiribelli M, Guella A, Innella B, Vivaldi P, De Biasi E, Sancetta R, Rocconi R, Bassan R, Gherlinzoni F, Pizzolo G, Gastl G, Cortelazzo S.

Intern Emerg Med. 2015 Jun;10(4):451-60. doi: 10.1007/s11739-015-1186-8. Epub 2015 Jan 14.

PMID:
25585678
40.

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R.

Am J Hematol. 2015 Apr;90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2.

41.

Ulcerative skin metastases of primary lung cancer.

Pircher A, Gastl G, Heidegger I.

Jpn J Clin Oncol. 2015 Jan;45(1):135. doi: 10.1093/jjco/hyu213. No abstract available.

PMID:
25542961
42.

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, Stenehjem D, Brixner D, Radich J, Gastl G, Siebert U.

Leuk Lymphoma. 2015;56(8):2315-25. doi: 10.3109/10428194.2014.982635. Epub 2015 Jan 14.

PMID:
25393806
43.

The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics.

Boesch M, Zeimet AG, Reimer D, Schmidt S, Gastl G, Parson W, Spoeck F, Hatina J, Wolf D, Sopper S.

Oncotarget. 2014 Aug 30;5(16):7027-39.

44.

(68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT.

Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, Gautsch K, Madleitner R, Nilica B, Sprinzl GM, Gastl G, Fraedrich G, Virgolini IJ.

Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):33-41. doi: 10.1007/s00259-014-2892-6. Epub 2014 Aug 19.

PMID:
25134670
45.

Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.

Pircher A, Gamerith G, Amann A, Reinold S, Popper H, Gächter A, Pall G, Wöll E, Jamnig H, Gastl G, Wolf AM, Hilbe W, Wolf D.

Lung Cancer. 2014 Jul;85(1):81-7. doi: 10.1016/j.lungcan.2014.04.001. Epub 2014 Apr 13.

PMID:
24780112
46.

Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas.

Fong D, Seeber A, Terracciano L, Kasal A, Mazzoleni G, Lehne F, Gastl G, Spizzo G.

J Clin Pathol. 2014 May;67(5):408-14. doi: 10.1136/jclinpath-2013-201932. Epub 2014 Jan 24.

47.

Systematic assessment of decision-analytic models for chronic myeloid leukemia.

Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U.

Appl Health Econ Health Policy. 2014 Apr;12(2):103-15. doi: 10.1007/s40258-013-0071-8. Review.

PMID:
24385259
48.

Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.

Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL.

Ann Hematol. 2014 Feb;93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30.

PMID:
24292560
49.

Essential thrombocytemia progressing to Ph+ chronic myeloid leukemia with megakaryoblastic blasts, following anagrelide withdrawal.

Piccin A, Corvetta D, Rovigatti U, Mazzoleni G, Pusceddu I, Svaldi M, Steurer M, Gastl G, Cortelazzo S.

Platelets. 2014;25(8):646-7. doi: 10.3109/09537104.2013.858112. Epub 2013 Nov 8. No abstract available.

PMID:
24205832
50.

Medical decision analysis for first-line therapy of chronic myeloid leukemia.

Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, Brixner D, Radich J, Gastl G, Siebert U.

Leuk Lymphoma. 2014 Aug;55(8):1758-67. doi: 10.3109/10428194.2013.858149. Epub 2014 Feb 6.

PMID:
24160847

Supplemental Content

Support Center